Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more

被引:145
作者
Goldie, SJ
Kim, JJ
Wright, TC
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Harvard Ctr Risk Anal, Boston, MA 02115 USA
[2] Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA
关键词
D O I
10.1097/01.AOG.0000120143.50098.c7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To evaluate the cost-effectiveness of human papillomavirus (HPV) DNA testing as a primary screening test in combination with cervical cytology in women aged 30 years or more. METHODS: A state-transition mathematical model was used to simulate the natural history of HPV and cervical cancer in a cohort of U.S. women. Strategies included no screening and screening at different frequencies with conventional cytology, liquid-based cytology with HPV testing used for triage of equivocal results, and HPV DNA testing and cytology in combination after women had reached the age of 30. Outcomes measured included cancer incidence, life expectancy, lifetime costs, and incremental cost-effectiveness ratios. RESULTS: The estimated reduction in lifetime risk of cervical cancer varies from 81% to 93% depending on the screening frequency, type of cytology, and test strategy. Every 3-year screening with liquid-based cytology administered to women at all ages and every 3-year screening using HPV DNA testing and cytology in combination administered to women aged 30 years or more provide equivalent or greater benefits than those provided by annual conventional cytology and have incremental cost-effectiveness ratios of $95,300 and $228,700 per year of life gained, respectively. In comparison, annual screening with HPV DNA testing and cytology in combination provides only a few hours of additional life expectancy and has a cost-effectiveness ratio of more than $2,000,000 per year of life gained. CONCLUSIONS: For women aged 30 years and more, every 2- or 3-year screening strategy that uses either HPV DNA testing in combination with cytology for primary screening or cytology with reflex HPV DNA testing for equivocal results will provide a greater reduction in cancer and be less costly than annual conventional cytology. (C) 2004 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:619 / 631
页数:13
相关论文
共 94 条
  • [1] [Anonymous], OBSTET GYNECOL
  • [2] ThinPrep Pap Test - Accuracy for glandular disease
    Ashfaq, R
    Gibbons, D
    Vela, C
    Saboorian, MH
    Iliya, F
    [J]. ACTA CYTOLOGICA, 1999, 43 (01) : 81 - 85
  • [3] DETERMINANTS OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION IN LOW-RISK WOMEN IN PORTLAND, OREGON
    BAUER, HM
    HILDESHEIM, A
    SCHIFFMAN, MH
    GLASS, AG
    RUSH, BB
    SCOTT, DR
    CADELL, DM
    KURMAN, RJ
    MANOS, MM
    [J]. SEXUALLY TRANSMITTED DISEASES, 1993, 20 (05) : 274 - 278
  • [4] Shanxi province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia
    Belinson, J
    Qiao, YL
    Pretorius, R
    Zhang, WH
    Elson, P
    Li, L
    Pan, QJ
    Fischer, C
    Lorincz, A
    Zahniser, D
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 83 (02) : 439 - 444
  • [5] The causal relation between human papillomavirus and cervical cancer
    Bosch, FX
    Lorincz, A
    Muñoz, N
    Meijer, CJLM
    Shah, KV
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) : 244 - 265
  • [6] Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing
    Brown, AD
    Garber, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (04): : 347 - 353
  • [7] Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors
    Burk, RD
    Kelly, P
    Feldman, J
    Bromberg, J
    Vermund, SH
    Dehovitz, JA
    Landesman, SH
    [J]. SEXUALLY TRANSMITTED DISEASES, 1996, 23 (04) : 333 - 341
  • [8] Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women
    Clavel, C
    Masure, L
    Bory, JP
    Putaud, I
    Mangeonjean, C
    Lorenzato, M
    Nazeyrollas, P
    Gabriel, R
    Quereux, C
    Birembaut, P
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (12) : 1616 - 1623
  • [9] HPV testing in primary screening of older women
    Cuzick, J
    Beverley, E
    Ho, L
    Terry, G
    Sapper, H
    Mielzynska, I
    Lorincz, A
    Chan, WK
    Krausz, T
    Soutter, P
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (03) : 554 - 558
  • [10] CUZICK J, 1999, HEALTH TECHNOL ASSES, V3, P14